News

Will the FDA Panel Vote Make NAD+ a Mainstream ...

A recent FDA panel vote on NMN has reignited debate over NAD+ as an anti-aging therapy. We review the science behind NAD+, GHK-Cu, Epitalon, and

GHK-Cu and Epitalon Synergy for Epigenetic Agin...

The FDA peptide panel vote reshapes longevity research. GHK-Cu and Epitalon show early promise for epigenetic clock reversal, but regulatory hurdles

GHK-Cu and Thymalin Synergy for Immune Rejuvena...

Explore how GHK-Cu and Thymalin may synergize for immune rejuvenation, and why recent GLP-1 compounding quality concerns highlight the critical

GHK-Cu and Epitalon Synergy for Telomere Suppor...

Explore how GHK-Cu and Epitalon may synergize for telomere support and epigenetic rejuvenation, with insights on NAD+, Vesugen, Cortagen, and